No connection

Search Results

ENOV vs NVCR

ENOV
Enovis Corporation
NEUTRAL
Price
$24.10
Market Cap
$1.39B
Sector
Healthcare
AI Confidence
80%
NVCR
NovoCure Limited
BEARISH
Price
$12.17
Market Cap
$1.38B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ENOV
--
NVCR
--
Forward P/E
ENOV
6.03
NVCR
-10.44
P/B Ratio
ENOV
0.93
NVCR
4.02
P/S Ratio
ENOV
0.62
NVCR
2.11
EV/EBITDA
ENOV
7.38
NVCR
-8.77

Profitability

Gross Margin
ENOV
60.88%
NVCR
74.8%
Operating Margin
ENOV
6.09%
NVCR
-21.33%
Profit Margin
ENOV
-52.69%
NVCR
-20.79%
ROE
ENOV
-58.27%
NVCR
-38.89%
ROA
ENOV
1.09%
NVCR
-9.06%

Growth

Revenue Growth
ENOV
2.6%
NVCR
8.1%
Earnings Growth
ENOV
--
NVCR
--

Financial Health

Debt/Equity
ENOV
0.92
NVCR
0.73
Current Ratio
ENOV
2.02
NVCR
2.9
Quick Ratio
ENOV
0.8
NVCR
2.51

Dividends

Dividend Yield
ENOV
--
NVCR
--
Payout Ratio
ENOV
0.0%
NVCR
0.0%

AI Verdict

ENOV NEUTRAL

Enovis Corporation presents a classic 'deep value' paradox, characterized by a stable Piotroski F-Score of 4/9 but severe bottom-line profitability issues. While the company trades at a significant discount to book value (P/B 0.93) and a very low forward P/E (6.03), its net profit margin is deeply negative at -52.69%. The stock is supported by a strong track record of earnings beats and bullish analyst targets, but this is countered by a disastrous long-term price trend and high execution risk associated with its acquisition-led growth strategy.

Strengths
Extreme valuation discount with Price/Book at 0.93 and Price/Sales at 0.62
Strong gross margins of 60.88% indicating a healthy core product value
Exceptional earnings track record with consistent beats over 25 quarters
Risks
Severe net losses resulting in a profit margin of -52.69% and negative ROE
High integration risk due to an aggressive acquisition-led growth strategy
Strong bearish technical momentum with a 5-year price decline of 68.9%
NVCR BEARISH

NVCR exhibits significant financial fragility with a weak Piotroski F-Score of 3/9 and a complete lack of positive deterministic value markers (Graham/Intrinsic). While the company maintains a strong gross margin of 74.8% and healthy short-term liquidity (Current Ratio 2.90), these are offset by persistent negative profit margins and a catastrophic 5-year price decline of 93.7%. The disconnect between bullish analyst targets ($25.07) and aggressive insider selling by the CFO and COO suggests a lack of internal confidence in near-term catalysts.

Strengths
High Gross Margin (74.80%) indicating strong product value
Strong short-term liquidity with a Current Ratio of 2.90
Improving EPS growth YoY (+63.9%) despite remaining negative
Risks
Weak financial health as indicated by Piotroski F-Score (3/9)
Severe long-term value destruction (-93.7% 5-year return)
Negative operating and profit margins (-21.33% and -20.79%)

Compare Another Pair

ENOV vs NVCR: Head-to-Head Comparison

This page compares Enovis Corporation (ENOV) and NovoCure Limited (NVCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile